why choose us

First received: August 02, 2023

Clinical Trial: TmCD19-IL18 in CD19+ Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase I Trial of TmCD19-IL18 CAR T Cells in Patients With Relapsed or Refractory CD19+ Cancers

Brief Summary: This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers.This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase.In the Dose-Finding Phase, up to 4 total dose levels will be evaluated using a 3+3 dose escalation design in order to determine the MTD (as defined below).Both…

Read more